8-K - Aprea Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds intended for general corporate purposes and research and development expenses.

Key Takeaways

1Closed a $30 million private placement financing on March 31, 2026, which was oversubscribed.

2Intends to use net proceeds for general corporate purposes and research and development expenses.

3The offering involved the sale of pre-funded warrants and warrants to purchase approximately 37.2 million shares each.

4Funding will support ongoing development of APR-1051, including expansion into selected patient populations.

5The private placement was led by Soleus Capital with participation from new and existing investors.

6The company plans to file a registration statement for the resale of the securities purchased.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or o

Regulation Fd

9.01

** **Financial Statements and Exhibits.** (d) Exhibits . | | | | |---|---|---| | Exhibit Number | | Description | | 99.1 | | Press Release of Ap

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1